Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2005
12/22/2005US20050281828 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/22/2005US20050281827 Trypanosome derived apoptotic factors (TAF)
12/22/2005US20050281820 Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives
12/22/2005US20050281783 Listeria-based EphA2 vaccines
12/22/2005CA2569909A1 Vaccine compositions and methods
12/22/2005CA2568336A1 Method for treating lupus
12/21/2005EP1606403A2 Hemipteran glutamate decarboxylase
12/21/2005EP1606381A2 Coated enzyme granules
12/21/2005EP1606305A2 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
12/21/2005EP1606303A2 Detection and monitoring of lung cancer
12/21/2005EP1606301A2 Aptamer therapeutics useful in ocular pharmacotherapy
12/21/2005EP1606297A2 High viscosity xanthan polymer preparations
12/21/2005EP1606283A2 P38 inhibitors and methods of use thereof
12/21/2005EP1606280A2 Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
12/21/2005EP1606266A2 Chemical compounds
12/21/2005EP1606255A2 Cyclic derivatives as modulators of chemokine receptor activity
12/21/2005EP1605978A2 Therapeutic compositions
12/21/2005EP1605974A2 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/21/2005EP1605970A2 Anti-cancer virus desensitization method
12/21/2005EP1605961A2 Polypeptide compounds for inhibiting angiogenesis and tumor growth
12/21/2005EP1605944A2 Quinoline derivatives as nk-2 and nk-3 receptor antagonists
12/21/2005EP1605940A1 METHOD FOR TREATING MILD COGNITIVE IMPAIRMENT AND FOR PREVENTING OR DELAYING ALZHEIMER’S DISEASE
12/21/2005EP1605900A2 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
12/21/2005EP1605897A2 Polyethelene glycol link glp-1 compounds
12/21/2005EP1605895A2 Oral insulin therapies and protocol
12/21/2005EP1605894A2 Oxytocin controlled release formulations and methods of using same
12/21/2005EP1605893A2 Trans-membrane-antibody induced inhibition of apoptosis
12/21/2005EP1605892A2 Combination of an aldosterone receptor antagonist and an anti-diabetic agent
12/21/2005EP1605862A2 Collagen compositions and biomaterials
12/21/2005EP1605764A2 Composition and method for appetite and carvingsuppressission and mood enhancement
12/21/2005EP1605763A2 Newcastle disease virus administration
12/21/2005EP1450834B1 Allium sativum bulb absolutes and therapeutic or cosmetic uses
12/21/2005EP1200053B1 Stable hydrogenated lupulone antibacterial oral compositions
12/21/2005CN1711097A Anti-angiogenesis effects of morinda citrifolia
12/21/2005CN1711073A Medicine composition containing octreotide grains
12/20/2005US6977311 enantiomerically pure; converting pyroglutamic acid, salt or ester to a 4-enamine derivative; hydrolysis to a 4-hydroxymethylidene derivative; reduction; and decyclization using a strong base
12/20/2005US6977298 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/20/2005CA2329703C Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
12/20/2005CA2290966C Sertraline salts and sustained-release dosage forms of sertraline
12/15/2005WO2005117577A2 Model for neurodegenerative disorders
12/15/2005WO2005079155A3 Photoreactive compound specifically binding to calcium binding proteins
12/15/2005WO2005055952A3 Synergistic anti-cancer compositions
12/15/2005WO2005048914A3 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
12/15/2005WO2005046592A3 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
12/15/2005WO2005046565A3 Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
12/15/2005WO2005046564A3 Diagnosis and treatment of liver fibrosis
12/15/2005WO2005044195A3 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
12/15/2005WO2005039507A3 Antimicrobial and antiviral compounds
12/15/2005WO2005034874A3 Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
12/15/2005WO2005030120A3 Antiangiogenic agents
12/15/2005WO2005018576A3 N-desmethyl-n-substituted-11-deoxyerythromycin compounds
12/15/2005WO2005013913A3 Peroxygen containing particle in an alcohol containing gel
12/15/2005WO2005011597A8 Compounds and compositions as protein kinase inhibitors
12/15/2005WO2005009371A3 Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system
12/15/2005WO2004105699A3 Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
12/15/2005WO2004100864A3 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases
12/15/2005WO2004091526A3 Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies
12/15/2005WO2004091507A3 Optimal polyvalent vaccine for cancer
12/15/2005WO2004089309A3 Conposition and methods for inhibiting fungal growth and transference
12/15/2005WO2004073633A3 Methods and compositions for modulating the development of stem cells
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004064787A3 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
12/15/2005WO2004064737A3 Therapeutics compositions
12/15/2005WO2004062616A3 Method of treating cognitive decline due to sleep deprivation and stress
12/15/2005WO2004056317A8 Compositions for the treatment and prevention of nephropathy
12/14/2005EP1604982A1 Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
12/14/2005EP1604683A2 Subcutaneously-administered ganglioside-based vaccine compositions
12/14/2005EP1604207A2 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
12/14/2005EP1604205A2 Methods and compositions related to joint inflammation diseases
12/14/2005EP1604023A2 Optimization of bacterial sucab expression by promoter mutagenesis for efficient l-glutamic acid production
12/14/2005EP1603933A2 Nitrosated and nitrosylated compounds, compositions and methods of use
12/14/2005EP1603900A2 Antiprotozoal imidazopyridine compounds
12/14/2005EP1603896A2 Cxcr3 antagonists
12/14/2005EP1603887A1 Hiv replication inhibiting pyrimidines and triazines
12/14/2005EP1603884A2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
12/14/2005EP1603881A2 Substituted thiophenes with antibacterial activity
12/14/2005EP1603879A2 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
12/14/2005EP1603864A2 Diphenylethylene compounds and uses thereof
12/14/2005EP1603607A2 Self-emulsifying compositions, methods of use and preparation
12/14/2005EP1603590A2 Influenza virus vaccine
12/14/2005EP1603573A2 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
12/14/2005EP1603570A2 Aminoheteroaryl compounds as protein kinase inhibitors
12/14/2005EP1603567A2 Tetracyclic benzamide derivatives and methods of use thereof
12/14/2005EP1603555A2 Halogenated triptolide derivatives as immunomodulators and anticancer agents
12/14/2005EP1603549A2 Improved bioavailability and improved delivery of acidic pharmaceutical drugs
12/14/2005EP1603548A2 Method and composition for treating neurodegenerative disorders
12/14/2005EP1603541A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
12/14/2005EP1603540A2 A process for preparing sustained release tablets
12/14/2005EP1603537A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
12/14/2005EP1603535A2 Aromatase inhibitor diagnosis and therapy
12/14/2005EP1603534A2 A method of treating a systemic disease
12/14/2005EP1603532A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
12/14/2005EP1603518A2 Poss and eposs containing cosmetics and personal care products
12/14/2005EP1603517A1 Skin care product containing tall oil fatty acids and vegetable oils for dry and scaling skin and treatment of psoriasis, dermatitis, and eczemas
12/14/2005EP1603513A2 Treatment using dantrolene
12/14/2005EP1603512A2 Novel cyclosporins
12/14/2005EP1603511A2 Treatment of igai deposition diseases
12/14/2005EP1603509A2 Method and system for administering a drug
12/14/2005EP1603499A2 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
12/14/2005EP1603405A2 Methods for treating cancer using perna canaliculus component(s) and extracts of perna canaliculus
1 ... 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 ... 295